Sustained revenue erosion and coach attrition indicate no near-term catalyst. With FY guidance unchanged, watch for further coach declines and potential cost actions. The stock may continue to drift lower given the lack of inflection.
Price Chart
Executive Summary
Medifast reported Q1 2026 revenue of $76.0M, down 34.3% YoY, and a net loss of $0.19 per share, widening from a $0.07 loss a year ago. Active earning coaches fell 44.9% to 14,000, with management expecting further declines. FY 2026 guidance was maintained at $270-300M revenue and $(1.55)-$(2.75) EPS, but Q2 guidance of $60-80M revenue and $(0.50)-$(1.00) EPS signals continued pressure from GLP-1 competition.
Key Financial Metrics
Key Facts
- Q1 2026 revenue $76.0M vs $115.7M prior year, down 34.3%
- Net loss $(0.19) per diluted share vs $(0.07) prior
- Active earning coaches 14,000, down 44.9% YoY
- Q2 2026 guidance: revenue $60-80M, EPS $(0.50)-(1.00)
- FY 2026 guidance maintained: revenue $270-300M, EPS $(1.55)-(2.75)
- Cash and investments $168.9M, zero debt
Financial Impact
Revenue decline of 34.3% and widening losses; structural headwinds from GLP-1 adoption
Risk Factors
- Continued revenue decline from GLP-1 displacement
- Inability to stabilize coach network
- Cash burn if losses persist despite strong balance sheet
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001628280-26-029812 |
| Document: med-20260504.htm | 0001628280-26-029812 |
| Document: 0001628280-26-029812-index-headers.html | 0001628280-26-029812 |
| Document: 0001628280-26-029812-index.html | 0001628280-26-029812 |
| Document: 0001628280-26-029812.txt | 0001628280-26-029812 |
| 8-K Data (Synthetic) | 0001628280-26-029812 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 1d ago | 8-K | $11.56 | awaiting T+5 | — | $12.55 (+8.56%) |
Oct 15, 2026 12d ago | Press Release | $12.06 $12.17 | ▲ +0.91% | ▲ +1.93% | $12.55 (+4.06%) |
Oct 6, 2026 21d ago | Press Release | $11.51 $11.67 | ▲ +1.39% | ▲ +1.53% | $12.55 (+9.04%) |
Oct 1, 2026 26d ago | Press Release | $11.43 $11.43 | · 0.00% | ▼ −1.30% | $12.55 (+9.80%) |
Aug 28, 2026 8w ago | Insider Buy | $12.18 $12.63 | ▲ +3.69% | ▲ +3.59% | $12.55 (+3.04%) |
Aug 26, 2026 8w ago | Insider Buy | $12.22 $12.67 | ▲ +3.68% | ▲ +3.80% | $12.55 (+2.70%) |
Aug 21, 2026 9w ago | Insider Buy | $11.95 $12.18 | ▲ +1.92% | ▲ +1.45% | $12.55 (+5.02%) |
Jul 17, 2026 14w ago | 8-K | $10.26 $9.45 | ▼ −7.89% | ▼ −7.21% | $12.55 (+22.32%) |
Jun 1, 2026 21w ago | 8-K | $12.70 $12.10 | ▼ −4.72% | ▼ −1.97% | $12.55 (−1.18%) |
May 26, 2026 21w ago | 8-K | $12.72 $12.36 | ▼ −2.83% | ▼ −4.04% | $12.55 (−1.34%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers